Holen Sie sich die Stockscreener-App
48.73
2.42%
-1.21
Schlusskurs vom Vortag:
$49.94
Offen:
$49.44
24-Stunden-Volumen:
1.17M
Relative Volume:
1.15
Marktkapitalisierung:
$3.89B
Einnahmen:
$541.74M
Nettoeinkommen (Verlust:
$88.01M
KGV:
44.86
EPS:
1.0862
Netto-Cashflow:
$155.34M
1W Leistung:
+5.16%
1M Leistung:
+47.80%
6M Leistung:
+9.24%
1J Leistung:
+80.62%
1-Tages-Spanne:
$47.95
$49.75
1-Wochen-Bereich:
$44.93
$50.54
52-Wochen-Spanne:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
48.73 | 3.98B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Jefferies | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Underweight |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Hold |
| 2025-03-20 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-16 | Eingeleitet | UBS | Buy |
| 2024-10-10 | Eingeleitet | Guggenheim | Buy |
| 2024-02-23 | Bestätigt | Needham | Buy |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-11-18 | Fortgesetzt | Goldman | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Outperform |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2019-07-31 | Eingeleitet | Lake Street | Buy |
| 2019-07-02 | Eingeleitet | Needham | Buy |
| 2018-11-29 | Herabstufung | Janney | Buy → Neutral |
| 2018-10-31 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-07 | Herabstufung | Janney | Buy → Neutral |
| 2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Fortgesetzt | BTIG Research | Buy |
| 2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-11 | Bestätigt | Leerink Partners | Outperform |
| 2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
FMR LLC holds 8.06M Veracyte (VCYT) shares, representing 10.1% - Stock Titan
Veracyte Insider Sold Shares Worth $6,919,585, According to a Recent SEC Filing - marketscreener.com
Veracyte CFO Rebecca Chambers sells $177,082 in company stock By Investing.com - Investing.com Canada
Veracyte global chief commercial off sells $699,732 in stock By Investing.com - Investing.com Canada
Veracyte EVP Annie McGuire sells $158k in company stock By Investing.com - Investing.com Canada
Veracyte CEO Marc Stapley sells $6.9m in company shares By Investing.com - Investing.com Canada
Veracyte CFO Rebecca Chambers sells $177,082 in company stock - Investing.com
Veracyte (VCYT) CFO trades shares as RSUs vest and 10b5-1 plan executes - Stock Titan
Veracyte (VCYT) CCO sells 13,975 shares under 10b5-1 plan, keeps 132K - Stock Titan
Veracyte global chief commercial off sells $699,732 in stock - Investing.com
Veracyte CEO Marc Stapley sells $6.9m in company shares - Investing.com
[144] VERACYTE, INC. SEC Filing - stocktitan.net
VCYT (NASDAQ) insider 10b5-1 sale of 10,204 shares; 3,176 RSUs registered - Stock Titan
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call - Yahoo Finance
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report? - Yahoo Finance
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate CancerSlideshow (NASDAQ:VCYT) 2026-06-03 - Seeking Alpha
Veracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
Veracyte stock price target maintained at $42 by Canaccord on study results - Investing.com
Veracyte (VCYT) Launches Prosigna Breast Cancer Risk Test in the U.S. - GuruFocus
Wolfe Research initiates Veracyte stock coverage with Outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates Veracyte stock coverage with Outperform rating - Investing.com
VCYT Maintained by Needham -- Price Target Raised to $57.00 - GuruFocus
Needham raises Veracyte stock price target to $57 on trial data By Investing.com - Investing.com South Africa
Needham raises Veracyte stock price target to $57 on trial data - Investing.com Australia
Veracyte (VCYT) Launches Prosigna Breast Risk Test for Cancer Pr - GuruFocus
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Veracyte launches Prosigna breast cancer test in U.S. By Investing.com - Investing.com Australia
Veracyte Inc Investor Call on ASCO Findings Transcript - GuruFocus
Veracyte launches Prosigna breast cancer test in U.S. - Investing.com
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S. - standard-journal.com
Veracyte Inc stock (US92347M1009): Nasdaq diagnostics name steadies after recent gains - AD HOC NEWS
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer - BioSpace
Breast and prostate cancer test data: Veracyte schedules June 1 call - Stock Titan
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy - BioSpace
Veracyte (VCYT) Unveils Promising Findings from Enzamet Trial - GuruFocus
Veracyte Says Enzamet Trial Shows Decipher Prostate Test Identifies Chemotherapy Benefit In Metastatic Prostate Cancer - TradingView
Study shows which prostate cancer patients can safely skip chemotherapy - Stock Titan
Here's how much you'd have if you invested $1000 in Veracyte a decade ago - MSN
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Ve - The National Law Review
A Look at Veracyte Inc (VCYT) After 7.8% Gain -- GF Value $37.84 vs Price $47.99 - GuruFocus
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform (NASDAQ:VCYT) - Seeking Alpha
Veracyte chief accounting officer sells $1.09m in stock By Investing.com - Investing.com Nigeria
Veracyte chief accounting officer sells $1.09m in stock - Investing.com
Veracyte (VCYT) CAO exercises options and sells 24,000 shares in Form 4 filing - Stock Titan
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now? - TradingView
Veracyte genomic test identifies breast cancer patients who can skip chemo - whbl.com
How Veracyte Inc. (VCYT) Affects Rotational Strategy Timing - Stock Traders Daily
Here's why Veracyte (VCYT) is a strong momentum stock - MSN
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Veracyte Inc-Aktie (VCYT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chambers Rebecca | Chief Financial Officer |
Jun 04 '26 |
Sale |
49.73 |
3,561 |
177,083 |
173,280 |
| Stapley Marc | Chief Executive Officer |
Jun 04 '26 |
Option Exercise |
36.60 |
138,051 |
5,052,667 |
578,545 |
| Stapley Marc | Chief Executive Officer |
Jun 04 '26 |
Sale |
50.12 |
138,051 |
6,919,585 |
440,494 |
| Leite John | Global Chief Commercial Off |
Jun 04 '26 |
Sale |
50.07 |
13,975 |
699,732 |
132,305 |
2.13%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):